98 related articles for article (PubMed ID: 22607960)
1. Targeting cyclin D1 for high risk myelodysplastic syndromes.
Mundle SD
Leuk Res; 2012 Aug; 36(8):964-5. PubMed ID: 22607960
[No Abstract] [Full Text] [Related]
2. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Olnes MJ; Shenoy A; Weinstein B; Pfannes L; Loeliger K; Tucker Z; Tian X; Kwak M; Wilhelm F; Yong AS; Maric I; Maniar M; Scheinberg P; Groopman J; Young NS; Sloand EM
Leuk Res; 2012 Aug; 36(8):982-9. PubMed ID: 22524974
[TBL] [Abstract][Full Text] [Related]
3. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Nazha A; Sekeres MA; Komrokji R; Steensma DP; Kantarjian H; Roboz G; Fenaux P; Prebet T; Azarnia N; Zbyszewski PS; Fruchtman SM; Santini V; Silverman LR; Platzbecker U; Garcia-Manero G
Blood Cancer J; 2017 Dec; 7(12):644. PubMed ID: 29238044
[No Abstract] [Full Text] [Related]
4. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
5. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Seetharam M; Fan AC; Tran M; Xu L; Renschler JP; Felsher DW; Sridhar K; Wilhelm F; Greenberg PL
Leuk Res; 2012 Jan; 36(1):98-103. PubMed ID: 21924492
[TBL] [Abstract][Full Text] [Related]
6. New therapeutics for myelodysplastic syndromes.
List AF
Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol Suppresses Growth and Migration of Myelodysplastic Cells by Inhibiting the Expression of Elevated Cyclin D1 (CCND1).
Zhou W; Xu S; Ying Y; Zhou R; Chen X
DNA Cell Biol; 2017 Nov; 36(11):966-975. PubMed ID: 29035583
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
9. [Molecular target therapy for myelodysplastic syndrome].
Morita Y; Tanaka H; Matsumura I
Nihon Rinsho; 2012 Nov; 70 Suppl 8():508-12. PubMed ID: 23513892
[No Abstract] [Full Text] [Related]
10. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan AC; O'Rourke JJ; Praharaj DR; Felsher DW
Expert Opin Investig Drugs; 2013 Nov; 22(11):1495-509. PubMed ID: 23937225
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
12. [I. Outlook on molecular targeting therapy for myelodysplastic syndrome].
Mitani K
Gan To Kagaku Ryoho; 2012 May; 39(5):732-5. PubMed ID: 22701899
[No Abstract] [Full Text] [Related]
13. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes.
Saberwal G; Broderick E; Janssen I; Shetty V; Alvi S; Lisak L; Venugopal P; Raza A; Mundle SD
J Hematother Stem Cell Res; 2003 Aug; 12(4):443-50. PubMed ID: 12965081
[TBL] [Abstract][Full Text] [Related]
14. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
15. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
16. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
17. A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.
Chen J; Zurawski G; Zurawski S; Wang Z; Akagawa K; Oh S; Hideki U; Fay J; Banchereau J; Song W; Palucka AK
J Hematol Oncol; 2015 Apr; 8():35. PubMed ID: 25888530
[TBL] [Abstract][Full Text] [Related]
18. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
19. [Epigenetic therapy in myelodysplastic syndromes].
Maki K; Mitani K
Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
[No Abstract] [Full Text] [Related]
20. Established and emerging targeted therapies in the myelodysplastic syndromes.
Canaani J; Nagler A
Expert Rev Hematol; 2016 Oct; 9(10):997-1005. PubMed ID: 27615383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
